Furthermore, the poor effect of anti-PD-1/PD-L1 immunotherapy in some patients with leukemia could be explained by the neglected expression of Gal-9 and CD122, which would reveal the possibility of new molecular targets for checkpoint immunotherapies. This evidence concerns the gene IL2RB and leukemia.